Skip Navigation

Phase I Trial Of Alpelisib Plus Sacituzumab Govitecan In Patients With Metastatic Or Locally Recurrent HER2-Negative Breast Cancer

Brief Summary

Type:
Breast Cancer

Study Type:
Treatment

Phase:
I

ClinicalTrials.gov Identifier:
NCT05143229

Study #:
STUDY00147815

Start Date:
Mar 27, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05143229

View Complete Trial Details & Eligibility at ClinicalTrials.gov